More News! 28 Oct 2019 UK Company Synthesizes Long DNA Molecules with 85% Accuracy The UK biotech Camena Bioscience has proven it can synthesize long DNA molecules with more accuracy than traditional chemical synthesis. Camena tested its technology’s ability to accurately synthesize DNA molecules with a length of 300 nucleotides — the building blocks of DNA. Using Camena’s technology, 85% of the synthesized DNA molecules were accurate to the […] October 28, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
More News! 17 Oct 2019 Sofinnova Partners Raises €333M for its Newest Life Sciences-Focused Fund Sofinnova Partners, Europe’s largest VC focused on life sciences, has raised €333M to fund early-stage healthcare companies, bringing the total capital managed by the firm to €2B. Sofinnova Partners aims to invest around two-thirds of the new fund, called Sofinnova Capital IX, in European life science companies. The other third will be invested globally, with […] October 17, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
More News! 11 Oct 2019 RNA Therapy Improves Vision in Untreatable Genetic Blindness A phase I/II trial run by the Dutch company ProQR has found that its RNA therapy could significantly improve the vision of people with Leber’s congenital amaurosis, a rare genetic disease for which there is no treatment. The RNA drug, called sepofarsen, is designed to treat people with a specific mutation in a gene […] October 11, 2019 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
More News! 9 Oct 2019 Novo Nordisk and Bluebird Bio to Treat Hemophilia with Gene Editing The Danish big pharma Novo Nordisk has joined forces with the US gene therapy company bluebird bio to develop next-generation gene editing treatments for hemophilia. The collaboration will last for three years and has the goal of developing a gene therapy that can permanently treat hemophilia A, a genetic disease causing uncontrolled bleeding. Novo Nordisk […] October 9, 2019 - 1 minutemin - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
More News! 8 Oct 2019 Israeli Biotech 3D Prints the First Beef Steak in Space Hungry astronauts rejoice! Aleph Farms, a company that grows beef steak from animal cells, has grown the first steaks aboard the International Space Station. The Israeli biotech’s experiment is the first proof that meat can be grown in outer space. Aleph Farms created the meat using a 3D bioprinter developed by the Russian company 3D […] October 8, 2019 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
More News! 7 Oct 2019 UK Biotech Launches with €30M Series A to Treat Autoimmune Disease MiroBio has spun out of the University of Oxford with a Series A round of €30M (£27M) to develop treatments for autoimmune diseases that don’t disrupt the immune system as a whole. The big Series A round accompanying MiroBio’s launch was co-led by the university’s investor partner Oxford Sciences Innovation and the US investor Samsara […] October 7, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
More News! 2 Oct 2019 Engineered Crop Plants Produce Fat Molecules for Formula Milk A team from the Rothamsted Research center, UK, has developed plants capable of mass-producing fat molecules resembling those in human breast milk. The scientists modified the way a type of oilseed plant generates fat molecules by introducing a mutation that changed the location within the cell of an enzyme responsible for processing fat. As a […] October 2, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
More News! 23 Sep 2019 AC Immune Gets €28M from Eli Lilly as Alzheimer’s Drug Hits Phase I AC Immune will receive €27.6M (CHF 30M) from big pharma Eli Lilly as it begins a phase I trial of its first-in-class Alzheimer’s disease drug. This is the first milestone payment in a deal worth up to €1.6B (CHF 1.7B), which Eli Lilly and AC Immune signed to develop drugs for Alzheimer’s and other neurodegenerative […] September 23, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
More News! 18 Sep 2019 €15M to Take Swiss Biotech’s Liver Cirrhosis Treatment to Phase II Versantis has raised a Series B of €14.6M (CHF 16M) to advance its treatment for late-stage liver cirrhosis to a phase IIa trial. The money will finance the completion of an ongoing phase I trial of Versantis’ lead candidate for the condition decompensated liver cirrhosis. Following this, the company will use the funds to launch […] September 18, 2019 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
More News! 12 Sep 2019 French Biotech to Develop Septic Shock Therapy with €39M Series B The French company Inotrem has raised €39M to fund an immunotherapy for septic shock, an often deadly condition caused by infections in the bloodstream. Led by the Hong Kong investor Morningside Ventures, the Series B round will finance a phase IIb trial of Inotrem’s lead candidate drug nangibotide, expected to start in November this year. […] September 12, 2019 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
More News! 11 Sep 2019 Dutch Company Raises €60M to Treat Inherited Inflammatory Disease The Dutch pharmaceutical company Pharvaris has raked in €60M in a Series B round to fund the clinical development of the first oral treatment for hereditary angioedema, a condition that causes swelling in the limbs and airways. The Series B round will fuel the clinical progress of Pharvaris’ oral small molecule treatment for hereditary angioedema, […] September 11, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
More News! 22 Aug 2019 French Biotech Withdraws US Application for its Living Biocide The US Environment Protection Agency (EPA) has stated it cannot grant registration to a biocide developed by Lyon-based company Amoéba for water treatment in cooling towers. Amoéba’s shares on Euronext Paris went down by 30% on Tuesday following the announcement. The biocide treatment consists of a live strain of amoeba called Willaertia magna C2c Maky. This […] August 22, 2019 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email